Topline results from phase II study shows oral neuroactive steroid GABAA receptor positive allosteric modulator (SAGE-324) significantly reduces tremor score in adult patients with essential tremor

Data from the KINETIC study (n=67) met the primary endpoint, showing treatment with SAGE-324 significantly reduced Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale, by day 29 vs. placebo (36% reduction from baseline; p=0.049).

Source:

Biospace Inc.